SPEEDX
18.3.2021 08:02:09 CET | Business Wire | Press release
SpeeDx have announced signing a new distribution partner, further extending customer access to market-leading SpeeDx Resistance Plus® and Plex PCR® tests. Neogen Diagnostik Sağlık Hizmetleri Ltd Şti will distribute all SpeeDx tests throughout Turkey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005254/en/
“We continue to see demand for our key tests and technology around the world,” says Warwick Need, SpeeDx Director of Sales. “Neogen Diagnostik are a great fit for SpeeDx products and we are looking forward to working with them to give Turkish laboratories the opportunity to provide ResistancePlus tests and support the use of Resistance Guided Therapy with their clinician partners.”
In addition to Resistance Plus GC* - combining Neisseria gonorrhoeae (GC) detection with markers for ciprofloxacin susceptibility, and Resistance Plus MG* - simultaneously detecting Mycoplasma genitalium and genetic markers for azithromycin resistance, the SpeeDx sexual health portfolio includes Plex PCR VHS* - a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis), and Plex PCR HSV-1&2, VZV.
SpeeDx are also growing their Respiratory portfolio with the recently launched Plex PCR RespiVirus - a comprehensive multiplex panel for respiratory virus testing, and the soon to be launched Plex PCR SARS-CoV-2 test – a dual target COVID-19 assay for confident detection of all currently known circulating variants. A respiratory bacterial infection testing solution will also be launched this year.
“Neogen Diagnostik is pleased to make Resistance Guided Therapy available to all stakeholders in the Turkey healthcare chain from clinicians and lab specialists to patients through this distributorship deal with SpeeDx. This is absolutely of medical value complementing the rational use of antibiotics when treating patients. SpeeDx solutions will be a real diagnostic tool for clinicians when deciding on the best possible treatment options for their patients,” Abdulmecit Arikan, founder of Neogen Diagnostik, said in a statement.
*available where CE-mark is accepted, not available in the U.S.
About SpeeDx Pty Ltd
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. SpeeDx has a portfolio of CE-IVD kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers. SpeeDx Resistance Plus tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.
For more information about SpeeDx please see: http://plexpcr.com
About Neogen Diagnostik Sağlık Hizmetleri Ltd Şti
Neogen Diagnostik is a medical company founded by Abdulmecit Arikan, a Molecular Biologist with 18 years of experience in executive positions at a leading multinational diagnostics company and 20+ years corporate experience. Neogen Diagnostik is committed to providing access to advanced technologies used for diagnostic purposes in healthcare, believing that innovative technologies with value-based solutions can eliminate the existing obstacles in molecular diagnostics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005254/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MultiBank Exchange Holding Forms Predominantly Emirati Board as Platform Records US$500 Billion in Monthly Trading Volume4.11.2026 18:54:00 CET | Press release
MultiBank Group has announced the formation of a predominantly Emirati Board of Directors for MultiBank Exchange Holding, the first interbank trading platform in the BRICS and emerging countries, which achieved in October 2026 a turnover of over US$ 0.5 Trillion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104483253/en/ Naser Taher, Chairman of MultiBank Exchange Holding, announced the board which comprises: H.H. Sheikh Juma bin Maktoum bin Juma Al Maktoum, Board Member; H.E. Sheikh Mohammed bin Saqr bin Rashid Al Nuaimi, Board Member; H.E. Mohammed Al Hakim, Vice Chairman of the Board; H.E. Ali bin Khalid bin Zayed Al Falasi, Board Member; H.E. Rashid Sultan Al Malik, Board Member; Mr. Majid Al Ghaslan, Board Member; and Mr. David Ogg, Board Member. Naser Taher, Chairman of MultiBank Exchange Holding, announced the board which comprises: H.H. Sheikh Juma bin Maktoum bin Juma Al Maktoum, Board Member. H.E. Sheikh Moham
SES Achieves Optical Communications Milestone for Future meoSphere Network4.11.2026 18:00:00 CET | Press release
High speed data transfers send SES’s CEO to space, advancing meoSphere optical network SES, in collaboration with leading space technology partners, has successfully demonstrated a bi-directional optical communications link between ground and space through its meoSphere Pathfinder 1 mission, marking an important milestone in the development of the company's next-generation meoSphere network. The achievement validates a critical technology that will support future high-capacity, secure and flexible connectivity services. During the demonstration, SES successfully transmitted video messages from CEO Adel Al-Saleh over a bidirectional optical communications link between Cailabs' optical ground station in Rennes, France, and an SES payload flying on K2’s GRAVITAS mission on their Mega-class satellite platform. The mission utilized a Mynaric CONDOR optical terminal onboard. SES designed, developed, and operated the optical mission and developed automation software that enabled the demonstra
Smartsheet Unveils vsActual: The AI-Native Platform that Connects Strategy to Execution at ENGAGE 20264.11.2026 18:00:00 CET | Press release
vsActual closes the gap between strategic planning and execution, connecting systems, tracking and reporting to planning, so teams and leaders can catch drift while it’s still fixable Smartsheet, the AI-powered enterprise work management platform, today unveiled a new AI-native strategic planning and execution product at ENGAGE 2026, its annual customer conference. vsActual is designed to solve the two biggest obstacles to enterprise execution: siloed work scattered across disconnected systems and teams, and the manual tracking and reporting that keeps individuals and executives from seeing problems until it’s too late. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104989965/en/ Today, Smartsheet unveiled a new AI-native strategic planning and execution product, vsActual. AI is helping individuals move faster than ever, but it's also making it harder to keep everyone moving in the same direction. In fact, a PMI research
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom